Expands software portfolio and nonclinical drug development expertise
Certara, Inc., a global leader in biosimulation, announced on January 5, 2022 the acquisition of Integrated Nonclinical Development Solutions, Inc. (INDS), a company that provides the SEND Explorer® software and drug development consulting with a focus on nonclinical and toxicology support.
"We are thrilled to join Certara and be part of a bigger future together," said James R. Herman, President of INDS. "This is a great fit on multiple levels – technology, talent and mission to accelerate medicines. We are enthusiastic about the opportunities this combination presents for INDS and our clients."
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. More information about the acquisition may be found here.
The specialized, complementary expertise of our team members enables INDS to provide you drug development support from target selection to product registration. Our data management and information technology specialists work closely with our toxicologists to deliver software solutions that truly reflect end-user needs for ease-of-use and flexibility. Our team consists of board certified toxicologists, veterinarians, and information technology and business operations experts with more than 100 years of combined experience in the pharmaceutical and contract research industries.
Whether you lack internal safety expertise or need to supplement your internal resources to meet peak demands, contact INDS. We have the know-how you need to succeed.